Athanasios Manolis
Research Subjects
Athanasios Manolis has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Manolis S. Kallistratos
Cardiology Department, Metropolitan Hospital, Piraeus, Greece
2 shared publications Alberto Mazza
Internal Medicine Unit, Department of Medicine, ESH Excellence Center Unit, Italy
1 shared publicationAlexandre Persu
Department of Cardiovascular Diseases, Division of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
1 shared publication- Andreas Pittaras
Pharmacology Laboratory, Department of Medicine, University of Patras, Rio Achaias, 26500 Patras, Greece
1 shared publication - Anna Oliveras
Department of Nephrology, Hospital del Mar, Pompeu Fabra University, 08003 Barcelona, Spain
1 shared publication - Béatrice Bouhanick
Department of Internal Medicine and Hypertension, University Hospital Rangueil, TSA 50032, 31059 Toulouse cedex 9, France
1 shared publication
Latest Publications
- 10 April 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 149, 106863
Erectile dysfunction and antihypertensive therapy: A critical reappraisal
- 10 April 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 149, 106863
Erectile dysfunction and antihypertensive therapy: A critical reappraisal
- Open Access
- 23 June 2024
- Published by Taylor & Francis in Blood Pressure
- Vol. 33 (1) , 2368800
Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney
Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70-95%]) than MRA (20% [10-30%]), SGLT2i (30% [20-50%]) or (GLP1-RA (10% [5-15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15-40%) vs 18% [10%-25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5-5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers' dosage reduction was the usual management.
- 23 June 2024
- Published by Taylor & Francis in Blood Pressure
- Vol. 33 (1) , 2368800
Open AccessManagement of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney
Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70-95%]) than MRA (20% [10-30%]), SGLT2i (30% [20-50%]) or (GLP1-RA (10% [5-15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15-40%) vs 18% [10%-25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5-5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers' dosage reduction was the usual management.
- 7 June 2016
- Published by Springer Nature
- p. 13-20
Comorbidities Often Associated with Brain Damage in Hypertension: Dyslipidaemia
- 7 June 2016
- Published by Springer Nature
- p. 13-20
Comorbidities Often Associated with Brain Damage in Hypertension: Dyslipidaemia
- 16 December 2014
- Published by H1 Connect
Faculty Opinions recommendation of Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
In this trial, 45 patients receiving antihypertensive drugs with uncontrolled hypertension underwent catheter-based renal denervation. They showed a significant reduction in systolic and diastolic blood pressure of 14 and 10mmHg, respectively, after 4 weeks, 27 and 17mmHg after 12 months (p<0.026), and 33 and 19mmHg after 36 months (p<0.1), but there are long-term data for only 24 patients {-4}. This Recommendation is of an article referenced in an F1000Prime Report also written by Athanasios J. Manolis, Manolis S. Kallistratos, Michalis Doumas, Stamatina Pagoni, and Leonidas Poulimenos.
- 16 December 2014
- Published by H1 Connect
Faculty Opinions recommendation of Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
In this trial, 45 patients receiving antihypertensive drugs with uncontrolled hypertension underwent catheter-based renal denervation. They showed a significant reduction in systolic and diastolic blood pressure of 14 and 10mmHg, respectively, after 4 weeks, 27 and 17mmHg after 12 months (p<0.026), and 33 and 19mmHg after 36 months (p<0.1), but there are long-term data for only 24 patients {-4}. This Recommendation is of an article referenced in an F1000Prime Report also written by Athanasios J. Manolis, Manolis S. Kallistratos, Michalis Doumas, Stamatina Pagoni, and Leonidas Poulimenos.
- 16 December 2014
- Published by H1 Connect
Faculty Opinions recommendation of A controlled trial of renal denervation for resistant hypertension.
These disappointing results from this randomized controlled trial sequel to {1-3} found that catheter-based renal denervation was no better than optimal medical treatment. 535 patients with severe resistant hypertension were randomly assigned in a 2:1 ratio to undergo renal denervation or a sham procedure. The study failed to achieve both its primary and secondary efficacy endpoints. The mean reduction in office blood pressure was 14.1mmHg with active therapy and 11.7mmHg with placebo at 6 months, and was highly significant for both groups compared to the baseline (p<0.001), but the difference between the two groups was small (2.4mmHg) and not significant (p=0.26). Similarly, the mean systolic blood pressure reduction in 24-hour ambulatory blood pressure at 6 months was 6.8mmHg with active therapy and 4.8mmHg with placebo compared to the baseline, and the small difference between the two groups (2.0mmHg) was not significant (p=0.98). However, there are some questions that remain before accepting this trial as definitive. For example, did the study include only real resistant hypertensives or some uncontrolled hypertension patients? Also, the number of ablations per patient was significantly related to the degree of success, so it would be important to know that the degree of skill with catheter-based renal denervation was comparable with previous studies. This Recommendation is of an article referenced in an F1000Prime Report also written by Athanasios J. Manolis, Manolis S. Kallistratos, Michalis Doumas, Stamatina Pagoni, and Leonidas Poulimenos.
- 16 December 2014
- Published by H1 Connect
Faculty Opinions recommendation of A controlled trial of renal denervation for resistant hypertension.
These disappointing results from this randomized controlled trial sequel to {1-3} found that catheter-based renal denervation was no better than optimal medical treatment. 535 patients with severe resistant hypertension were randomly assigned in a 2:1 ratio to undergo renal denervation or a sham procedure. The study failed to achieve both its primary and secondary efficacy endpoints. The mean reduction in office blood pressure was 14.1mmHg with active therapy and 11.7mmHg with placebo at 6 months, and was highly significant for both groups compared to the baseline (p<0.001), but the difference between the two groups was small (2.4mmHg) and not significant (p=0.26). Similarly, the mean systolic blood pressure reduction in 24-hour ambulatory blood pressure at 6 months was 6.8mmHg with active therapy and 4.8mmHg with placebo compared to the baseline, and the small difference between the two groups (2.0mmHg) was not significant (p=0.98). However, there are some questions that remain before accepting this trial as definitive. For example, did the study include only real resistant hypertensives or some uncontrolled hypertension patients? Also, the number of ablations per patient was significantly related to the degree of success, so it would be important to know that the degree of skill with catheter-based renal denervation was comparable with previous studies. This Recommendation is of an article referenced in an F1000Prime Report also written by Athanasios J. Manolis, Manolis S. Kallistratos, Michalis Doumas, Stamatina Pagoni, and Leonidas Poulimenos.
- 22 June 2014
- Published by Taylor & Francis
- p. 476-485
HYPERTENSION AND ATRIAL FIBRILLATION: MODERN EPIDEMIOLOGIC, PATHOPHYSIOLOGIC, AND THERAPEUTIC ASPECTS
- 22 June 2014
- Published by Taylor & Francis
- p. 476-485
HYPERTENSION AND ATRIAL FIBRILLATION: MODERN EPIDEMIOLOGIC, PATHOPHYSIOLOGIC, AND THERAPEUTIC ASPECTS
- Open Access
- 16 January 2014
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 27 (3) , 422-430
Statin Therapy, Fitness, and Mortality Risk in Middle-Aged Hypertensive Male Veterans
Hypertension often coexists with dyslipidemia, accentuating cardiovascular risk. Statins are often prescribed in hypertensive individuals to lower cardiovascular risk. Higher fitness is associated with lower mortality, but exercise capacity may be attenuated in hypertension. The combined effects of fitness and statin therapy in hypertensive individuals have not been assessed. Thus, we assessed the combined health benefits of fitness and statin therapy in hypertensive male subjects. Peak exercise capacity was assessed in 10,202 hypertensive male subjects (mean age = 60.4±10.6 years) in 2 Veterans Affairs Medical Centers. We established 4 fitness categories based on peak metabolic equivalents (METs) achieved and 8 categories based on fitness status and statin therapy. During the follow-up period (median = 10.2 years), there were 2,991 deaths. Mortality risk was 34% lower (hazard ratio (HR) = 0.66; 95% confidence interval (CI) = 0.59–0.74; P < 0.001) among individuals treated with statins compared with those not on statins. The fitness-related mortality risk association was inverse and graded regardless of statin therapy status. Risk reduction associated with exercise capacity of 5.1–8.4 METs was similar to that observed with statin therapy. However, those achieving ≥8.5 METs had 52% lower risk (HR = 0.48; 95% CI = 0.37–0.63) when compared with the least-fit subjects (≤5 METs) on statin therapy. The combination of statin therapy and higher fitness lowered mortality risk in hypertensive individuals more effectively than either alone. The risk reduction associated with moderate increases in fitness was similar to that achieved by statin therapy. Higher fitness was associated with 52% lower mortality risk when compared with the least fit subjects on statin therapy.
- 16 January 2014
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 27 (3) , 422-430
Open AccessStatin Therapy, Fitness, and Mortality Risk in Middle-Aged Hypertensive Male Veterans
Hypertension often coexists with dyslipidemia, accentuating cardiovascular risk. Statins are often prescribed in hypertensive individuals to lower cardiovascular risk. Higher fitness is associated with lower mortality, but exercise capacity may be attenuated in hypertension. The combined effects of fitness and statin therapy in hypertensive individuals have not been assessed. Thus, we assessed the combined health benefits of fitness and statin therapy in hypertensive male subjects. Peak exercise capacity was assessed in 10,202 hypertensive male subjects (mean age = 60.4±10.6 years) in 2 Veterans Affairs Medical Centers. We established 4 fitness categories based on peak metabolic equivalents (METs) achieved and 8 categories based on fitness status and statin therapy. During the follow-up period (median = 10.2 years), there were 2,991 deaths. Mortality risk was 34% lower (hazard ratio (HR) = 0.66; 95% confidence interval (CI) = 0.59–0.74; P < 0.001) among individuals treated with statins compared with those not on statins. The fitness-related mortality risk association was inverse and graded regardless of statin therapy status. Risk reduction associated with exercise capacity of 5.1–8.4 METs was similar to that observed with statin therapy. However, those achieving ≥8.5 METs had 52% lower risk (HR = 0.48; 95% CI = 0.37–0.63) when compared with the least-fit subjects (≤5 METs) on statin therapy. The combination of statin therapy and higher fitness lowered mortality risk in hypertensive individuals more effectively than either alone. The risk reduction associated with moderate increases in fitness was similar to that achieved by statin therapy. Higher fitness was associated with 52% lower mortality risk when compared with the least fit subjects on statin therapy.